HERMES
Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with preserved ejection fraction and systemic inflammation
- Stadium
- followup
- Middel
- Ziltivekimab
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 22 mei 2023
- Last Patient In
- 30 september 2025
- Last Patient Last Visit
- 2 juli 2027
National Lead
prof. dr. R.A. de Boer
Cardioloog
Studiedirecteur
dr. C.J.W. Borleffs
Cardioloog
Contact Kantoor
